Home > Gastroenterology > ECCO 2020 > Experimental Therapies: Study Results > Open-label extension study of risankizumab: final results

Open-label extension study of risankizumab: final results

Presented By
Dr M. Ferrante, University Hospitals Leuven, Belgium
Conference
ECCO 2020
In a final analysis of long-term treatment with open-label risankizumab in Crohn’s disease (CD), its safety profile remained consistent with previous data, with no new safety signals. Clinical remission as well as endoscopic remission was sustained [1]. Responders to risankizumab, an IL-23A antibody, in a phase 2 induction/maintenance study could enrol in an open-label extension (OLE). They received open-label 180 mg subcutaneous risankizumab every 8 weeks for up to 206 weeks. There were 65 CD patients who enrolled in the OLE, with 4 patients re-induced; 60 patients (92%) had been previously treated with TNF antagonists. In the OLE, median exposure to risankizumab was 1,014 (range: 114–1,317) days. At baseline of the current study, 47 patients (72%) had clinical remission, defined as Crohn’s disease Activity Index (CDAI) <150. At baseline, 27 patients (42%) were in endoscopic remission, defined as Crohn’s disease Endoscopic Index of Severity (CDE...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on